
- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
Azathioprine is an immunosuppressive drug that is marketed under the brand names Imuran and others. Rheumatoid arthritis, granulomatosis with polyangiitis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, and kidney transplants to prevent rejection are among conditions it is used to treat.
To stop the rejection of a transplanted kidney, azathioprine is utilized. It is a member of the class of drugs known as immunosuppressive agents. Azathioprine will reduce a patient's natural immunity after transplantation in order to prevent rejection of the new kidney.
Azathioprine is used to treat a variety of autoimmune illnesses, including rheumatoid arthritis, pemphigus, and pemphigus vulgaris, as well as to avoid rejection after organ transplantation.
The Global Azathioprine Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
An immunomodulator called azathioprine has a number of significant side effects. Age, genetic predispositions, and drug dosage all affect how toxic it is. The patient's cooperation is limited by its negative side effects. As a result, frequent laboratory testing and routine follow-up are essential to preventing its consequences.
Even in patients who are asymptomatic, clinicians and pharmacists should be aware of potential side effects of AZA. The remainder of the healthcare team should be informed of any disparities by pharmacists who have confirmed the dosage is suitable for the disease being treated.
Azathioprine is a purine analogue that, through the actions of the enzymes hypoxanthine-guanine phosphoribosyl transferase (HPRT) and thiopurine methyltransferase (TPMT), transforms into its active metabolites, mercaptopurine (6-MP) and thioguanine (6-TGN).
It then prevents the production of purines. Its metabolites stop division by integrating with the DNA that is duplicating. The majority of AZA's toxic and immunosuppressive effects may also be mediated by its metabolites.
AZA quickly passes through the digestive tract but does not cross the blood-brain barrier. Its liver-based metabolism and kidney-based excretion make it more hazardous in cases of renal failure.
A drug called azathioprine (AZA) is used to control and treat active rheumatoid arthritis (RA), as well as to stop kidney transplant rejection. This activity discusses the benefits of azathioprine as a treatment for RA and other conditions when appropriate, as well as its actions and contraindications.
The mechanism of action, adverse event profile, and other significant elements important for members of the interprofessional team in the treatment of patients with RA and related illnesses will be highlighted in this exercise.
Sl no | Topic |
1 | Market Segmentation |
2 | Scope of the report |
3 | Abbreviations |
4 | Research Methodology |
5 | Executive Summary |
6 | Introduction |
7 | Insights from Industry stakeholders |
8 | Cost breakdown of Product by sub-components and average profit margin |
9 | Disruptive innovation in the Industry |
10 | Technology trends in the Industry |
11 | Consumer trends in the industry |
12 | Recent Production Milestones |
13 | Component Manufacturing in US, EU and China |
14 | COVID-19 impact on overall market |
15 | COVID-19 impact on Production of components |
16 | COVID-19 impact on Point of sale |
17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
21 | Product installation rate by OEM, 2023 |
22 | Incline/Decline in Average B-2-B selling price in past 5 years |
23 | Competition from substitute products |
24 | Gross margin and average profitability of suppliers |
25 | New product development in past 12 months |
26 | M&A in past 12 months |
27 | Growth strategy of leading players |
28 | Market share of vendors, 2023 |
29 | Company Profiles |
30 | Unmet needs and opportunity for new suppliers |
31 | Conclusion |
32 | Appendix |